Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Dana-Farber Cancer Institute
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
75High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07610733CT.gov Impact of Formulation Change on Ovarian Suppression in Young Breast Cancer Patients. | — | Not Yet Recruiting | — | — | — |
NCT07349069CT.gov A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer | — | Recruiting | — | — | — |
NCT06434064CT.gov Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer | — | Recruiting | — | — | — |
NCT07502820CT.gov The POWER Trial: Personalised Dose Optimisation With Adjuvant Tamoxifen Therapy in Breast cancER | — | Not Yet Recruiting | — | — | — |
NCT07071038CT.gov Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients | — | Recruiting | — | — | — |
NCT07101159CT.gov Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients | — | Not Yet Recruiting | — | — | — |
NCT06630325CT.gov A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer | — | Terminated | — | — | — |
NCT06348134CT.gov Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery | — | Recruiting | — | — | — |
NCT07190443CT.gov Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA) | — | Recruiting | — | — | — |
NCT06492616CT.gov A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence | — | Recruiting | — | — | — |
Show 146 more trialsShow fewer
NCT06409390CT.gov Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | — | Recruiting | — | — | — |
NCT06179303CT.gov Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer | — | Recruiting | — | — | — |
NCT06154590CT.gov Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor | — | Not Yet Recruiting | — | — | — |
NCT06346457CT.gov Breast Cancer & Antiestrogenic Therapy & Brain | — | Unknown | — | — | — |
NCT05512364CT.gov Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) | — | Recruiting | — | — | — |
NCT05952557CT.gov An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) | — | Recruiting | — | — | — |
NCT06001762CT.gov TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT05894239CT.gov A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer | — | Recruiting | — | — | — |
NCT05659563CT.gov Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10% | — | Completed | — | — | — |
NCT05826964CT.gov Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT05891093CT.gov Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) | — | Recruiting | — | — | — |
NCT05861830CT.gov Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES) | — | Recruiting | — | — | — |
NCT05768139CT.gov First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05774951CT.gov A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | — | Recruiting | — | — | — |
NCT05780567CT.gov Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT05101564CT.gov Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer | — | Completed | — | — | — |
NCT05333328CT.gov OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk | — | Recruiting | — | — | — |
NCT05982093CT.gov Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer | — | Recruiting | — | — | — |
NCT05645536CT.gov Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study | — | Enrolling By Invitation | — | — | — |
NCT05463601CT.gov Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT05296798CT.gov A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) | — | Active Not Recruiting | — | — | — |
NCT05161195CT.gov Roll-over Study to Allow Continued Access to Ribociclib | — | Active Not Recruiting | — | — | — |
NCT05472792CT.gov Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy | — | Recruiting | — | — | — |
NCT05207514CT.gov Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer | — | Terminated | — | — | — |
NCT05131893CT.gov Neoadjuvant Treatment of Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT05128773CT.gov Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity | — | Terminated | — | — | — |
NCT05035836CT.gov A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC) | — | Recruiting | — | — | — |
NCT04997941CT.gov Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients | — | Active Not Recruiting | — | — | — |
NCT04961996CT.gov A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) | — | Active Not Recruiting | — | — | — |
NCT05016349CT.gov Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer. | — | Unknown | — | — | — |
NCT04906395CT.gov Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04190056CT.gov Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer | — | Terminated | — | — | — |
NCT04852081CT.gov Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study. | — | Unknown | — | — | — |
NCT04584853CT.gov PreOperative Endocrine Therapy for Individualised Care With Abemaciclib | — | Active Not Recruiting | — | — | — |
NCT04433494CT.gov A Study of TY-302 in Patients With Advanced Solid Tumors | — | Unknown | — | — | — |
NCT04300790CT.gov Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients | — | Completed | — | — | — |
NCT05110170CT.gov Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX® | — | Completed | — | — | — |
NCT04504331CT.gov Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer | — | Terminated | — | — | — |
NCT04460430CT.gov Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT03554044CT.gov T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer | — | Completed | — | — | — |
NCT04059484CT.gov Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer | — | Terminated | — | — | — |
NCT03879174CT.gov Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation | — | Unknown | — | — | — |
NCT03691493CT.gov Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis | — | Completed | — | — | — |
NCT02913430CT.gov Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib | — | Completed | — | — | — |
NCT03906669CT.gov A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer. | — | Unknown | — | — | — |
NCT03373708CT.gov Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer | — | Unknown | — | — | — |
NCT03045653CT.gov Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer | — | Completed | — | — | — |
NCT03161353CT.gov Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy. | — | Active Not Recruiting | — | — | — |
NCT02668666CT.gov Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer | — | Completed | — | — | — |
NCT02476786CT.gov Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score | — | Recruiting | — | — | — |
NCT02747004CT.gov A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02764541CT.gov Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS) | — | Active Not Recruiting | — | — | — |
NCT02624973CT.gov PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial | — | Active Not Recruiting | — | — | — |
NCT02630693CT.gov Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer | — | Completed | — | — | — |
NCT02914158CT.gov Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women | — | Unknown | — | — | — |
NCT02586675CT.gov TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer | — | Completed | — | — | — |
NCT02384239CT.gov A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer | — | Completed | — | — | — |
NCT02535221CT.gov Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer | — | Recruiting | — | — | — |
NCT02333370CT.gov A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer | — | Completed | — | — | — |
NCT02322853CT.gov A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors | — | Terminated | — | — | — |
NCT02291913CT.gov Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer | — | Completed | — | — | — |
NCT02404844CT.gov Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer | — | Completed | — | — | — |
NCT02269670CT.gov Phase II Study of Everolimus Beyond Progression | — | Terminated | — | — | — |
NCT02278120CT.gov Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer | — | Completed | — | — | — |
NCT02285179CT.gov Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen | — | Completed | — | — | — |
NCT05800197CT.gov Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia | — | Unknown | — | — | — |
NCT02132000CT.gov Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients | — | Unknown | — | — | — |
NCT02890082CT.gov Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT01950182CT.gov Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer | — | Completed | — | — | — |
NCT01674140CT.gov S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT01622361CT.gov Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer | — | Unknown | — | — | — |
NCT01564056CT.gov Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment | — | Active Not Recruiting | — | — | — |
NCT01503905CT.gov Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients | — | Unknown | — | — | — |
NCT02866955CT.gov Evaluation of the Efficacy of Estramustine in Patient With Breast Cancer Progression After Treatment With Aromatase Inhibitor. | — | Completed | — | — | — |
NCT00667121CT.gov Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline | — | Completed | — | — | — |
NCT01194427CT.gov A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer | — | Terminated | — | — | — |
NCT01192308CT.gov PharmacoKINEtics of TAMoxifen and Its Metabolites in Breast Cancer Patients: the Influence of a Dose Increase in Phenotypic Poor Metabolizers of CYP2D6 (KINETAM) | — | Completed | — | — | — |
NCT01194908CT.gov Re-expression of ER in Triple Negative Breast Cancers | — | Terminated | — | — | — |
NCT01896050CT.gov Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer | — | Completed | — | — | — |
NCT00852332CT.gov Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer | — | Terminated | — | — | — |
NCT00912548CT.gov Evaluating the Role of the Addition of Ovarian Function Suppression (OFS) to Tamoxifen in Young Women | — | Unknown | — | — | — |
NCT00873366CT.gov Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer | — | Terminated | — | — | — |
NCT00728949CT.gov A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer | — | Completed | — | — | — |
NCT00738777CT.gov Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer | — | Suspended | — | — | — |
NCT01352091CT.gov Adjuvant AI Combined With Zoladex | — | Unknown | — | — | — |
NCT00847366CT.gov Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma | — | Completed | — | — | — |
NCT00659373CT.gov Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02 | — | Completed | — | — | — |
NCT00605267CT.gov Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment | — | Completed | — | — | — |
NCT00493649CT.gov Adj TC + Herceptin Early Stage Breast Cancer | — | Completed | — | — | — |
NCT00433589CT.gov Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes | — | Completed | — | — | — |
NCT00372424CT.gov Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive | — | Completed | — | — | — |
NCT00424164CT.gov Lapatinib and Tamoxifen in Treating Patients With Advanced or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00398489CT.gov Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery | — | Unknown | — | — | — |
NCT00499083CT.gov Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women) | — | Completed | — | — | — |
NCT00365599CT.gov Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer | — | Completed | — | — | — |
NCT00127933CT.gov XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer | — | Completed | — | — | — |
NCT00118157CT.gov Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen | — | Completed | — | — | — |
NCT00412022CT.gov HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer. | — | Unknown | — | — | — |
NCT00080743CT.gov Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00129896CT.gov Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients | — | Completed | — | — | — |
NCT00066690CT.gov Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer | — | Completed | — | — | — |
NCT00148668CT.gov Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer | — | Completed | — | — | — |
NCT00066703CT.gov Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer | — | Completed | — | — | — |
NCT00066807CT.gov Premenopausal Endocrine Responsive Chemotherapy Trial | — | Terminated | — | — | — |
NCT00206492CT.gov Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients | — | Terminated | — | — | — |
NCT00052728CT.gov Tipifarnib Plus Tamoxifen in Treating Women With Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00053911CT.gov Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer | — | Terminated | — | — | — |
NCT00089479CT.gov A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer | — | Completed | — | — | — |
NCT00206466CT.gov Biologic Correlative Taxotere/AC | — | Completed | — | — | — |
NCT01831076CT.gov Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors | — | Completed | — | — | — |
NCT02748213CT.gov A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00206453CT.gov Extension Neoadjuvant Taxotere: Study of the Effects of Taxotere in Patients With Breast Cancer | — | Terminated | — | — | — |
NCT00253539CT.gov Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer | — | Completed | — | — | — |
NCT00047099CT.gov Combination Chemotherapy in Treating Women With Breast Cancer | — | Completed | — | — | — |
NCT00016276CT.gov Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer | — | Terminated | — | — | — |
NCT00005886CT.gov Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer | — | Completed | — | — | — |
NCT00005908CT.gov Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer | — | Completed | — | — | — |
NCT00005822CT.gov SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer | — | Completed | — | — | — |
NCT00003906CT.gov Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women | — | Completed | — | — | — |
NCT00206505CT.gov Neoadjuvant Taxotere | — | Completed | — | — | — |
NCT00003680CT.gov Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer | — | Unknown | — | — | — |
NCT00003972CT.gov Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer | — | Completed | — | — | — |
NCT00003352CT.gov Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer | — | Completed | — | — | — |
NCT00003199CT.gov Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer | — | Completed | — | — | — |
NCT00003042CT.gov Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer | — | Completed | — | — | — |
NCT00002967CT.gov Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer | — | Completed | — | — | — |
NCT00003032CT.gov High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer | — | Completed | — | — | — |
NCT00002920CT.gov S9630, Medroxyprogesterone in Treating Women With Breast Cancer | — | Completed | — | — | — |
NCT00002864CT.gov Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer | — | Completed | — | — | — |
NCT00590785CT.gov Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394) | — | Completed | — | — | — |
NCT00152178CT.gov The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC) | — | Completed | — | — | — |
NCT00002772CT.gov S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer | — | Terminated | — | — | — |
NCT00849030CT.gov ATAC - Arimidex, Tamoxifen Alone or in Combination | — | Completed | — | — | — |
NCT00002784CT.gov High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer | — | Completed | — | — | — |
NCT00003099CT.gov Chemoprevention Therapy Plus Surgery in Treating Women With Breast Cancer | — | Completed | — | — | — |
NCT00002755CT.gov Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer | — | Completed | — | — | — |
NCT00002646CT.gov Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer | — | Completed | — | — | — |
NCT00002680CT.gov Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00002644CT.gov Tamoxifen for the Prevention of Breast Cancer in High-Risk Women | — | Completed | — | — | — |
NCT00002582CT.gov Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer | — | Completed | — | — | — |
NCT00002580CT.gov Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer | — | Completed | — | — | — |
NCT00309491CT.gov Randomized Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal Receptor-positive Patients | — | Completed | — | — | — |
NCT00309478CT.gov Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients | — | Completed | — | — | — |
NCT00929591CT.gov SWOG-8814 Tamoxifen With or Without Combination Chemotherapy in Postmenopausal Women Who Have Undergone Surgery for Breast Cancer | — | Completed | — | — | — |
NCT00002460CT.gov Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer | — | Unknown | — | — | — |
NCT00793377CT.gov Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tamoxifen (this asset) | Dana-Farber Cancer Institute | Approved | BB · 69 |
| Darolutamide | Vandana Abramson | P2 | BBB |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Palbociclib | Hoffmann-La Roche | P4 | BB |
| Trastuzumab Duocarmazine | Byondis B.V. | P3 | BB |
| Goserelin | TerSera Therapeutics LLC | P4 | BB |
| Ribociclib | National Cancer Institute (NCI) | P4 | BB |
| Oxaliplatin | Beijing Biostar Pharmaceuticals Co., Ltd. | P4 | BB |
| Eribulin Monomethanesulfonate | Henan Cancer Hospital | P4 | BB |
+42 more in the Breast Cancer cohort
Other indications for Tamoxifen
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Invasive Breast Carcinoma | — | P4 | BBB · 75 |
| Breast Carcinoma | — | P4 | BBB · 75 |
| Breast Fibroadenoma | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tamoxifen in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tamoxifen-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →